As Korean biopharma firms, particularly bioventures, are suffering from a sharp decline in financing and licensing deals, the role of the state-supported Korea Drug Development Fund (KDDF) is becoming increasingly crucial to assist their R&D and business development activities and help weather the tough environment.
The KDDF was created in 2011, modelled after overseas agencies such as the US National Institutes of Health. The Korean fund is classed as a government agency and is supported...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?